Boston Scientific CORP: management transactions · United States · SEC (Form 4)

About Boston Scientific CORP

Boston Scientific Corp. is a global medical technology company listed in the United States on the NYSE under the ticker BSX. For French-speaking investors, it is a large-cap healthcare name exposed to structurally attractive end markets driven by aging populations, the rise of chronic disease, and continuous innovation in minimally invasive care. The company was founded in 1979 in Watertown, Massachusetts, and today has its world headquarters in Marlborough, Massachusetts, in the United States. Its corporate identity was built around interventional medicine, with a strategy focused on differentiated technologies and clinical niches where product innovation, physician adoption, and regulatory clearance create meaningful barriers to entry. ([bostonscientific.com](https://www.bostonscientific.com/content/dam/bostonscientific/corporate/annual-report/2024-annual-report-and-10-K.pdf.coredownload.pdf?utm_source=openai)) Boston Scientific reports through two major segments: MedSurg and Cardiovascular. Its portfolio spans electrophysiology and cardiac rhythm management, left atrial appendage closure, coronary and peripheral interventions, endoscopy, urology, and neuromodulation, along with certain minimally invasive surgical solutions. This diversification gives the company a resilient profile while also supporting above-average growth through a mix of mature franchises and newer platforms. Key product families include WATCHMAN, FARAPULSE, EKOS, EMBLEM MRI S-ICD, and a broad range of endoscopy and urology systems. ([news.bostonscientific.com](https://news.bostonscientific.com/interested-in-our-q4-2024-financial-results?utm_source=openai)) From a competitive standpoint, Boston Scientific ranks among the leading global players in implantable and interventional medical devices, competing with companies such as Medtronic, Abbott, Johnson & Johnson, and Edwards depending on the end market. Its edge comes from portfolio expansion, a strong innovation engine, and disciplined commercial execution across hospitals, electrophysiologists, interventional cardiologists, gastroenterologists, and urologists. The group also has a broad international footprint, with sales across multiple geographies and manufacturing and assembly capacity spread over several sites worldwide. ([bostonscientific.com](https://www.bostonscientific.com/content/dam/bostonscientific/corporate/annual-report/2024-annual-report-and-10-K.pdf.coredownload.pdf?utm_source=openai)) Recent developments reinforce that thesis. Boston Scientific reported first-quarter 2026 net sales of $5.203 billion, up 11.6% year over year, and fourth-quarter 2025 sales of $5.286 billion, with full-year 2025 revenue reaching $20.074 billion. The company also released positive clinical data for FARAPULSE and WATCHMAN, received FDA approvals and clearances for several products, and announced acquisitions including Bolt Medical. For investors, BSX remains a high-quality Healthcare / Pharma stock combining organic growth, innovation, and portfolio leverage on a liquid, closely followed U.S. equity market. ([news.bostonscientific.com](https://news.bostonscientific.com/2026-04-22-Boston-Scientific-announces-results-for-first-quarter-2026?utm_source=openai))